AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29784554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600mg pre-event
Number of subjects: 40
Study 29784554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29784554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pre-event to post-event)
Number of subjects: 40
Study 27456464 — intervention group
Group type: EXPERIMENTAL
Intervention: Colla corii asini (CCA) 15 g
Number of subjects: 72
Study 27456464 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 72
Study 24981506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant whole brain radiotherapy (WBRT) following local treatment of intracranial melanoma metastases
Number of subjects: 54
Study 24981506 — intervention group
Group type: COMPARATOR
Intervention: Pilot study accrual
Number of subjects: 54
Study 23053340 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroPulse (MP) treatment at the active leakage site guided by fluorescein angiography (n=16 eyes)
Number of subjects: 52
Study 23053340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg Bevacizumab (BCZ) (n=10 eyes)
Number of subjects: 52
Study 23053340 — intervention group
Group type: COMPARATOR
Intervention: Passive observation (Control group) (n=26 eyes)
Number of subjects: 52
Study 19775677 — intervention group
Group type: EXPERIMENTAL
Intervention: Social problem-solving strategies
Number of subjects: 439
Study 18344099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of fomepizole (15 mg/kg)
Number of subjects: 10
Study 18344099 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of fomepizole (15 mg/kg)
Number of subjects: 10
Study 17148777 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin (CTC group)
Number of subjects: 28
Study 17148777 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC group)
Number of subjects: 28
Study 17148777 — intervention group
Group type: COMPARATOR
Intervention: No systemic chemotherapy (no-CT group)
Number of subjects: 28
Study 17148777 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 28
Study 12663594 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid function tests (TSH, thyroxine, triiodothyronine) annually and TPO antibodies every 4 years
Number of subjects: 58
Study 12663594 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening by serum TSH measurement
Number of subjects: 58
Study 11177201 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A: 1000 g of 58Fe-labelled formula (1.44 mg total Fe/1000 g) as six feeds over 24 h
Number of subjects: 10
Study 11177201 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B: 1000 g of 58Fe-labelled formula (1.44 mg total Fe/1000 g) as two feeds/day on three consecutive days
Number of subjects: 10
Study 11177201 — intervention group
Group type: COMPARATOR
Intervention: Reference dose: Water solution with 57Fe and ascorbic acid
Number of subjects: 10
Study 8848320 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter sterile technique (handwash of 30 s and double gloving)
Number of subjects: 46
Study 8848320 — intervention group
Group type: COMPARATOR
Intervention: Longer sterile technique (3 minute wash from fingertips to elbows and wearing a sterile gown and one pair of gloves)
Number of subjects: 46
Study 1330470 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg/bid for 10.5 days
Number of subjects: 42
Study 1330470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3901660 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS60 (Na+ 60 mmol/l)
Number of subjects: 66
Study 3901660 — intervention group
Group type: COMPARATOR
Intervention: Commercial low sodium glucose-electrolyte solution (sodium 35 mmol/l, glucose 3.5 milligrams)
Number of subjects: 66
Study 29084918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontuxizumab (8 mg/kg) plus best supportive care
Number of subjects: 126
Study 29084918 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 126
Study 27353315 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session cue exposure therapy
Number of subjects: 45
Study 27353315 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 45
Study 25809304 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 36
Study 25809304 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 36
Study 25809304 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod pooled (0.5 mg and 1.25 mg)
Number of subjects: 36
Study 25809304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 23633161 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-to-Family (FTF) education program
Number of subjects: 442
Study 23633161 — intervention group
Group type: COMPARATOR
Intervention: Decliner population (those who declined RCT participation)
Number of subjects: 442
Study 20886731 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal-epidural anesthesia (SEA)
Number of subjects: 72
Study 20886731 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (SA)
Number of subjects: 72
Study 20886731 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (EA)
Number of subjects: 72
Study 18813409 — intervention group
Group type: EXPERIMENTAL
Intervention: Open HS hemorrhoidectomy (n=22)
Number of subjects: 87
Study 18813409 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed HS hemorrhoidectomy (n=22)
Number of subjects: 87
Study 18813409 — intervention group
Group type: EXPERIMENTAL
Intervention: Miligan Morgan hemorrhoidectomy (n=22)
Number of subjects: 87
Study 18813409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferguson hemorrhoidectomy (n=21)
Number of subjects: 87
Study 15734619 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg atorvastatin
Number of subjects: 40
Study 15734619 — intervention group
Group type: COMPARATOR
Intervention: 5 mg atorvastatin
Number of subjects: 40
Study 12783075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT)
Number of subjects: 0
Study 12783075 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CRT and defibrillator device
Number of subjects: 0
Study 12783075 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillators
Number of subjects: 0
Study 12783075 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CRT)
Number of subjects: 0
Study 10388298 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit care (SU)
Number of subjects: 14300
Study 10388298 — intervention group
Group type: COMPARATOR
Intervention: General ward care (GW)
Number of subjects: 14300
Study 8848472 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (aspirin and ibuprofen)
Number of subjects: 75
Study 8848472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 2049419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin
Number of subjects: 43
Study 2049419 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal vancomycin/aztreonam
Number of subjects: 43
Study 6338684 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous (150 to 200 cc/min) profound (4°C) topical hypothermia (Group A)
Number of subjects: 113
Study 6338684 — intervention group
Group type: EXPERIMENTAL
Intervention: Identical topical hypothermia plus one initial 500 cc aortic root bolus of cold (4°C) hyperkalemic cardioplegic solution (Group B)
Number of subjects: 113
Study 29396702 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% FMX103
Number of subjects: 232
Study 29396702 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% FMX103
Number of subjects: 232
Study 29396702 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 232
Study 29396702 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses (1.5% and 3% FMX103)
Number of subjects: 232
Study 28390209 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available toothpaste Pronamel® for Children (n = 82)
Number of subjects: 239
Study 28390209 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental plaque biofilm-loosening formula (PBF) toothpaste (n = 79)
Number of subjects: 239
Study 28390209 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Gentle Mint toothpaste (n = 78)
Number of subjects: 239
Study 28390209 — intervention group
Group type: COMPARATOR
Intervention: Control: biotène® Fresh Mint Original toothpaste (n = 82)
Number of subjects: 239
Study 28390209 — intervention group
Group type: COMPARATOR
Intervention: Control: biotène® Gentle Mint Gel toothpaste (n = 77)
Number of subjects: 239
Study 24507462 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Antithrombotic Risk Assessment Tool (CARAT) applied by GPs during consultations
Number of subjects: 500
Study 24507462 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without CARAT)
Number of subjects: 500
Study 24507462 — intervention group
Group type: EXPERIMENTAL
Intervention: CARAT applied at baseline and repeated at 12 months
Number of subjects: 500
Study 23753098 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group education modules (2 sessions, 6 sessions each) on early feeding practices
Number of subjects: 698
Study 23753098 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 698
Study 20713865 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasburicase (0.20 mg/kg/d intravenously days 1‐5)
Number of subjects: 275
Study 20713865 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasburicase plus allopurinol (rasburicase 0.20 mg/kg/d days 1 to 3 followed by oral allopurinol 300 mg/d days 3 to 5)
Number of subjects: 275
Study 20713865 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (300 mg/d orally days 1 to 5)
Number of subjects: 275
Study 20713865 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasburicase
Number of subjects: 275
Study 20713865 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasburicase plus allopurinol
Number of subjects: 275
Study 20713865 — intervention group
Group type: COMPARATOR
Intervention: Rasburicase, Rasburicase plus allopurinol, Allopurinol
Number of subjects: 275
Study 18672777 — intervention group
Group type: EXPERIMENTAL
Intervention: Hewei Xiaopi Capsule (HXC)
Number of subjects: 63
Study 18672777 — intervention group
Group type: COMPARATOR
Intervention: Domperidone (Control)
Number of subjects: 63
Study 16809591 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (model substance abuse program)
Number of subjects: 1370
Study 16809591 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1370
Study 15556742 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Assistants (MAs)
Number of subjects: 1221
Study 15556742 — intervention group
Group type: EXPERIMENTAL
Intervention: Licensed Practical Nurses (LPNs)
Number of subjects: 1221
Study 15556742 — intervention group
Group type: COMPARATOR
Intervention: Registered Nurses (RNs)
Number of subjects: 1221
Study 15556742 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline intervention
Number of subjects: 1221
Study 11023622 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed educational intervention
Number of subjects: 813
Study 11023622 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 813
Study 9132125 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 0.1% unconserved eyedrops (DICun) pre- and postoperatively
Number of subjects: 150
Study 9132125 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 0.1% conserved eyedrops (DICco) pre- and postoperatively
Number of subjects: 150
Study 9132125 — intervention group
Group type: EXPERIMENTAL
Intervention: DICun postoperatively
Number of subjects: 150
Study 9132125 — intervention group
Group type: EXPERIMENTAL
Intervention: DICun pre- and postoperatively, plus dexamethasone-21-dihydrogenphosphate 0.1% eyedrops (DEXA) postoperatively
Number of subjects: 150
Study 9132125 — intervention group
Group type: EXPERIMENTAL
Intervention: DEXA postoperatively
Number of subjects: 150
Study 8508194 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-complex supplementation (n = 22)
Number of subjects: 42
Study 8508194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 42
Study 3306893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg twice daily
Number of subjects: 28
Study 3306893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31743602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg and/or 100 mg daily (monotherapy)
Number of subjects: 1075
Study 31743602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg daily (add-on treatment)
Number of subjects: 1075
Study 31743602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study 29279527 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 67
Study 29279527 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (2.5 mg/day)
Number of subjects: 67
Study 27690320 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertile men (normozoospermic)
Number of subjects: 86
Study 27690320 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertile men (asthenozoospermic, oligozoospermic, oligoasthenozoospermic)
Number of subjects: 86
Study 27690320 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertile men (oligozoospermic, oligoasthenozoospermic, asthenozoospermic)
Number of subjects: 86
Study 27690320 — intervention group
Group type: COMPARATOR
Intervention: Fertile control
Number of subjects: 86
Study 24965954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health care using an oral moisture gel
Number of subjects: 142
Study 24965954 — intervention group
Group type: COMPARATOR
Intervention: Standard oral health care
Number of subjects: 142
Study 23093615 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins supplementation (folate, B12, B6)
Number of subjects: 359
Study 23093615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study 20504306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccine (15 microg HA/strain/0.1-ml dose)
Number of subjects: 795
Study 20504306 — intervention group
Group type: COMPARATOR
Intervention: Adjuvanted vaccine (15 microg HA/strain/0.5-ml dose) administered intramuscularly
Number of subjects: 795
Study 20504306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccine
Number of subjects: 795
Study 20504306 — intervention group
Group type: COMPARATOR
Intervention: Adjuvanted vaccine
Number of subjects: 795
Study 18839835 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic meropenem (Mapenem)
Number of subjects: 26
Study 18839835 — intervention group
Group type: COMPARATOR
Intervention: Original meropenem (Meronem)
Number of subjects: 26
Study 15812454 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg for infants and 20 mg for others)
Number of subjects: 0
Study 15812454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11919304 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA alone
Number of subjects: 2082
Study 11919304 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA plus abciximab
Number of subjects: 2082
Study 11919304 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting alone
Number of subjects: 2082
Study 11919304 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting plus abciximab
Number of subjects: 2082
Study 10334612 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received copies of their medical record progress notes and completed question lists for physician review.
Number of subjects: 205
Study 10334612 — intervention group
Group type: COMPARATOR
Intervention: Control group received health education sheets and completed suggestion lists for improving clinic care.
Number of subjects: 205
Study 8951590 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐type natriuretic peptide (ANP) infusion at 0.1 microgram/kg/min
Number of subjects: 0
Study 8951590 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐type natriuretic peptide (BNP) infusion at 0.1 microgram/kg/min
Number of subjects: 0
Study 2022158 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 10 mg every morning
Number of subjects: 270
Study 2022158 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg every morning
Number of subjects: 270
Study 2022158 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg twice a day
Number of subjects: 270
Study 7038142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (nephrectomy) and adjuvant active immunotherapy (bacillus Calmette‐Guerin)
Number of subjects: 20
Study 7038142 — intervention group
Group type: COMPARATOR
Intervention: Historical controls treated with conventional methods (hormones, chemotherapy, and radiotherapy with or without nephrectomy)
Number of subjects: 20
Study 29985724 — intervention group
Group type: EXPERIMENTAL
Intervention: KT without tension group (WTG)
Number of subjects: 54
Study 29985724 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 54
Study 29985724 — intervention group
Group type: EXPERIMENTAL
Intervention: KT tension group (TG)
Number of subjects: 54
Study 31432434 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS over Broca's area
Number of subjects: 12
Study 28905831 — intervention group
Group type: EXPERIMENTAL
Intervention: Goggles with side covers (Group A)
Number of subjects: 575
Study 28905831 — intervention group
Group type: COMPARATOR
Intervention: No safety eyewear (Group B)
Number of subjects: 575
Study 26325513 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 90
Study 26325513 — intervention group
Group type: COMPARATOR
Intervention: Macintosh
Number of subjects: 90
Study 25002195 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise programme (aerobic training and muscle strength training) for 3 months, supervised by telephone
Number of subjects: 41
Study 25002195 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (Control group)
Number of subjects: 41
Study 22178484 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard laparoscopic colectomy (SLC)
Number of subjects: 32
Study 22178484 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic colectomy (SILC)
Number of subjects: 32
Study 20810048 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2a (3 million units SC three times/week) + Ribavarin (1000 mg/day for weight ≤ 75kg; 1200 mg/day for weight > 75kg)
Number of subjects: 310
Study 20810048 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha 2b (3 million units SC three times/week) + Ribavarin (1000 mg/day for weight ≤ 75kg; 1200 mg/day for weight > 75kg)
Number of subjects: 310
Study 17469684 — intervention group
Group type: EXPERIMENTAL
Intervention: Various approaches to QOL assessment (patient self‐report, caregiver proxy report, observational assessment by trained observers)
Number of subjects: 0
Study 17469684 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia-specific measures of QOL
Number of subjects: 0
Study 17469684 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic measures of QOL
Number of subjects: 0
Study 17469684 — intervention group
Group type: COMPARATOR
Intervention: Clinical trials of pharmacotherapy for dementia
Number of subjects: 0
Study 16096860 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial venous surgery (SVS)
Number of subjects: 32
Study 12365884 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (Picibanil) sclerotherapy
Number of subjects: 30
Study 12365884 — intervention group
Group type: COMPARATOR
Intervention: Control group (observed for 6 months)
Number of subjects: 30
Study 10414910 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administration on day +1 (group B)
Number of subjects: 21
Study 10414910 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administration on day +7 (group C)
Number of subjects: 21
Study 10414910 — intervention group
Group type: COMPARATOR
Intervention: No G-CSF (group A)
Number of subjects: 21
Study 10414910 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administration (both early and delayed)
Number of subjects: 21
Study 10414910 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administration (early vs delayed)
Number of subjects: 21
Study 8528942 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of recombinant IFN‐alpha 2b 3 times a week for 6 months
Number of subjects: 22
Study 2221302 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous application of alfentanil (0.023 mg/kg b.w./h) and midazolam (0.10 mg/kg b.w./h)
Number of subjects: 30
Study 2221302 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous application of midazolam (0.13 mg/kg b.w./h) with continuously given alfentanil (0.028 mg/kg b.w./h)
Number of subjects: 30
Study 2221302 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous application of both substances
Number of subjects: 30
Study 2221302 — intervention group
Group type: EXPERIMENTAL
Intervention: Both substances
Number of subjects: 30
Study 6220415 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0
Study 6220415 — intervention group
Group type: COMPARATOR
Intervention: Massage
Number of subjects: 0
Study 6220415 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) and Massage
Number of subjects: 0
Study 30790597 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline (500 mg) and galantamine (16 mg)
Number of subjects: 24
Study 30790597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31313549 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbekacin sulphate 200 mg OD
Number of subjects: 162
Study 31313549 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin hydrochloride 1000 mg BD
Number of subjects: 162
Study 27263074 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care involvement triggered by length of stay > 8 days
Number of subjects: 220
Study 27263074 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire burden assessment
Number of subjects: 220